Microencapsulated chitosan nanoparticles for lung protein delivery.

It has already been demonstrated that spray drying is a very valuable technique for producing dry powders adequate for pulmonary delivery of drugs. We have developed chitosan/tripolyphosphate nanoparticles that promote peptide absorption across mucosal surfaces. The aim of this work was to microencapsulate protein-loaded chitosan nanoparticles using typical aerosol excipients, such as mannitol and lactose, producing microspheres as carriers of protein-loaded nanoparticles to the lung. The results showed that the obtained microspheres are mostly spherical and possess appropriate aerodynamic properties for pulmonary delivery (aerodynamic diameters between 2 and 3 microm, apparent density lower than 0.45 g/cm3). Moreover, microspheres morphology was strongly affected by the content of chitosan nanoparticles. These nanoparticles show a good protein loading capacity (65-80%), providing the release of 75-80% insulin within 15 min, and can be easily recovered from microspheres after contact with an aqueous medium with no significant changes in their size and zeta potential values. Therefore, this work demonstrated that protein-loaded nanoparticles could be successfully incorporated into microspheres with adequate characteristics to reach the deep lung, which after contact with its aqueous environment are expected to be able to release the nanoparticles, and thus, the therapeutic macromolecule.

[1]  I. El-Gibaly Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. , 2002, International journal of pharmaceutics.

[2]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[3]  María J. Alonso,et al.  Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration , 1999 .

[4]  M. Duszyk CFTR and lysozyme secretion in human airway epithelial cells , 2001, Pflügers Archiv.

[5]  M. Alonso,et al.  Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers , 1997 .

[6]  Christopher T. Rhodes,et al.  The spray drying of pharmaceuticals , 1992 .

[7]  V. Préat,et al.  Comparison of particle sizing techniques in the case of inhalation dry powders. , 2001, Journal of pharmaceutical sciences.

[8]  R. Langer,et al.  Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[9]  J. Patton,et al.  (D) Routes of delivery: Case studies , 1992 .

[10]  D. Walters Lung Lining Liquid – The Hidden Depths , 2002, Neonatology.

[11]  M. Alonso,et al.  Investigation of a pMDI system containing chitosan microspheres and P134a , 1998 .

[12]  D A Weitz,et al.  Trojan particles: Large porous carriers of nanoparticles for drug delivery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Buckton,et al.  The use of thermal techniques to assess the impact of feed concentration on the amorphous content and polymorphic forms present in spray dried lactose , 1997 .

[14]  G. Buckton,et al.  The effect of co-spray drying with polyethylene glycol 4000 on the crystallinity and physical form of lactose. , 2001, International journal of pharmaceutics.

[15]  H. M. Nielsen,et al.  The Potential of Chitosan in Enhancing Peptide and Protein Absorption Across the TR146 Cell Culture Model—An in Vitro Model of the Buccal Epithelium , 2002, Pharmaceutical Research.

[16]  T. Boat,et al.  Human lung lysozyme: sources and properties. , 1981, The American review of respiratory disease.

[17]  S. Schürch,et al.  Airway surfactant, a primary defense barrier: mechanical and immunological aspects. , 1996, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[18]  M. Khan,et al.  Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[19]  O. Mertins,et al.  Spray-dried indomethacin-loaded polyester nanocapsules and nanospheres: development, stability evaluation and nanostructure models. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[20]  Lisbeth Illum,et al.  Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2) , 1994, Pharmaceutical Research.

[21]  T. Vandamme,et al.  Pulmonary drug delivery systems: recent developments and prospects. , 2002, Critical reviews in therapeutic drug carrier systems.

[22]  M. Alonso,et al.  Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. , 2001, International journal of pharmaceutics.

[23]  J. Ward,et al.  Control of pH of airway surface liquid of the ferret trachea in vitro. , 1990, Journal of applied physiology.

[24]  S. Schürch,et al.  Surfactant displaces particles toward the epithelium in airways and alveoli. , 1990, Respiration physiology.

[25]  V. Préat,et al.  Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Claus-Michael Lehr,et al.  In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers , 1992 .

[27]  S. Akhtar,et al.  Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres , 1997 .

[28]  Y. Kawashima,et al.  A New Powder Design Method to Improve Inhalation Efficiency of Pranlukast Hydrate Dry Powder Aerosols by Surface Modification with Hydroxypropylmethylcellulose Phthalate Nanospheres , 1998, Pharmaceutical Research.

[29]  Gerrit Borchard,et al.  The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro , 1996 .

[30]  R. Müller,et al.  In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. I. Effect of analytical parameters, particle size and particle concentration , 1992 .

[31]  M. Alonso,et al.  Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches. , 1997, Biomaterials.

[32]  Kmg Taylor Pulmonary drug delivery , 2002 .

[33]  C. Remuñán-López,et al.  Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles , 1999, Pharmaceutical Research.

[34]  W. Finlay,et al.  Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. , 2000, International journal of pharmaceutics.

[35]  Yu Zhang,et al.  Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. , 2004, International journal of pharmaceutics.

[36]  L. Heinemann,et al.  Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. , 2000, Diabetes care.

[37]  H. Ohshima,et al.  Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres , 2003 .

[38]  J. Heyder,et al.  Deposition of particles in the human respiratory tract in the size range 0.005–15 μm , 1986 .

[39]  W. Finlay,et al.  Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols , 1997 .

[40]  George A. F. Roberts,et al.  Advances in chitin science , 1997 .

[41]  R. Muzzarelli,et al.  Human enzymatic activities related to the therapeutic administration of chitin derivatives , 1997, Cellular and Molecular Life Sciences CMLS.